agilon health, inc. Costs and Expenses
agilon health, inc. (AGL) reported Costs and Expenses of $1.48 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-05
- agilon health, inc. costs and expenses for the quarter ending 2026-06-30 was $1.48B, a 1.86% decline year-over-year.
- agilon health, inc. costs and expenses for the quarter ending 2026-03-31 was $1.42B, a 8.90% decline year-over-year.
- agilon health, inc. costs and expenses for the quarter ending 2025-12-31 was $1.76B, a 8.14% increase year-over-year.
- agilon health, inc. costs and expenses for the quarter ending 2025-09-30 was $1.57B, a 1.13% decline year-over-year.
- agilon health, inc. costs and expenses for fiscal 2025 was $6.40B, a 0.68% increase from fiscal 2024.
- agilon health, inc. costs and expenses for fiscal 2024 was $6.35B, a 39.67% increase from fiscal 2023.
- agilon health, inc. costs and expenses for fiscal 2023 was $4.55B, a 82.41% increase from fiscal 2022.
- agilon health, inc. costs and expenses for fiscal 2022 was $2.49B, a 31.68% increase from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 3 month as first filed | Costs and Expenses 6 month | Costs and Expenses 6 month as first filed | Costs and Expenses 9 month | Costs and Expenses 9 month as first filed | Costs and Expenses 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.48B 10-Q · filed 2026-08-05 | $2.90B 10-Q · filed 2026-08-05 | $4.66B derived: sum of 3 quarters · filed 2026-08-05 | $6.23B derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $1.42B 10-Q · filed 2026-05-06 | $3.18B derived: sum of 2 quarters · filed 2026-05-06 | $4.75B derived: sum of 3 quarters · filed 2026-05-06 | $6.26B derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $1.76B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.33B derived: sum of 2 quarters · filed 2026-02-25 | $4.84B derived: sum of 3 quarters · filed 2026-08-05 | $6.40B 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $1.57B 10-Q · filed 2025-11-04 | $3.08B derived: sum of 2 quarters · filed 2026-08-05 | $4.63B 10-Q · filed 2025-11-04 | $6.26B derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $1.51B 10-Q · filed 2026-08-05 | $3.07B 10-Q · filed 2026-08-05 | $4.70B derived: sum of 3 quarters · filed 2026-08-05 | $6.28B derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $1.55B 10-Q · filed 2026-05-06 | $3.19B derived: sum of 2 quarters · filed 2026-05-06 | $4.77B derived: sum of 3 quarters · filed 2026-05-06 | $6.30B derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $1.63B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.22B derived: sum of 2 quarters · filed 2026-02-25 | $4.74B derived: sum of 3 quarters · filed 2026-02-25 | $6.35B 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $1.58B 10-Q · filed 2025-11-04 | $3.11B derived: sum of 2 quarters · filed 2025-11-04 | $4.72B 10-Q · filed 2025-11-04 | $5.94B derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-06-30 | $1.53B 10-Q · filed 2025-08-04 | $3.14B 10-Q · filed 2025-08-04 | $4.36B derived: sum of 3 quarters · filed 2026-02-25 | $5.53B derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-03-31 | $1.61B 10-Q · filed 2025-05-06 | $2.83B derived: sum of 2 quarters · filed 2026-02-25 | $4.01B derived: sum of 3 quarters · filed 2026-02-25 | $5.11B derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2023-12-31 | $1.22B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.40B derived: sum of 2 quarters · filed 2026-02-25 | $3.49B derived: sum of 3 quarters · filed 2026-02-25 | $4.55B 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $1.18B 10-Q · filed 2024-11-07 | $1.26B 10-Q · filed 2023-11-02 | $2.27B derived: sum of 2 quarters · filed 2024-11-07 | $3.33B 10-Q · filed 2024-11-07 | $3.57B 10-Q · filed 2023-11-02 | $3.75B derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-06-30 | $1.10B 10-Q · filed 2024-08-06 | $1.18B 10-Q · filed 2023-08-03 | $2.15B 10-Q · filed 2024-08-06 | $2.31B 10-Q · filed 2023-08-03 | $2.58B derived: sum of 3 quarters · filed 2025-02-25 | $3.30B derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-03-31 | $1.05B 10-Q · filed 2024-05-07 | $1.48B derived: sum of 2 quarters · filed 2025-02-25 | $2.20B derived: sum of 3 quarters · filed 2025-02-25 | $2.89B derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2022-12-31 | $423.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.15B derived: sum of 2 quarters · filed 2025-02-25 | $1.84B derived: sum of 3 quarters · filed 2025-02-25 | $2.49B 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $724.38M 10-Q · filed 2023-11-02 | $1.42B derived: sum of 2 quarters · filed 2023-11-02 | $2.07B 10-Q · filed 2023-11-02 | ||||
| 2022-06-30 | $691.19M 10-Q · filed 2023-08-03 | $1.35B 10-Q · filed 2023-08-03 | |||||
| 2021-12-31 | $1.89B 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |